Inventor · disambiguated record
Ivanka Toudjarska
Also filed as: TOUDJARSKA IVANKA
20 granted patents·11 pending applications·108 citations·filing 2009–2023
94Inventor score
Files withALNYLAM PHARMACEUTICALS INC15BUMCROT DAVID4ARROWHEAD PHARMACEUTICALS INC3GENZYME CORP3GOLLOB JARED2
Top patents by PatentIndex Score
31 records- 0196US9127274B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS·Filed 2013·Granted Sep 8, 2015·51 cites·62 claims
- 0291US11198876B2Compositions and methods for inhibiting expression of TMPRSS6 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Dec 14, 2021·3 cites·23 claims
- 0391US9376680B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 28, 2016·7 cites·55 claims
- 0490US9725718B2Compositions and methods for inhibition of expression of protein C (PROC) genesALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 8, 2017·3 cites·33 claims
- 0590US8324368B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionGOLLOB JARED·Filed 2009·Granted Dec 4, 2012·12 cites·36 claims
- 0687US9175290B2Compositions and methods for inhibiting expression of TMPRSS6 geneBUMCROT DAVID·Filed 2012·Granted Nov 3, 2015·8 cites·37 claims
- 0785US9068184B2Compositions and methods for inhibition of expression of protein C (PROC) genesTOUDJARSKA IVANKA·Filed 2012·Granted Jun 30, 2015·5 cites·24 claims
- 0885US2023365965A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGENZYME CORP·Filed 2023·Application pending·0 cites
- 0984US10100312B2Compositions and methods for inhibiting expression of TMPRSS6 geneALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Oct 16, 2018·3 cites·21 claims
- 1082US8889644B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionGOLLOB JARED·Filed 2012·Granted Nov 18, 2014·5 cites·29 claims
- 1180US9006197B2Compositions and methods for inhibiting expression of Eg5 and VEGF genesBUMCROT DAVID·Filed 2012·Granted Apr 14, 2015·4 cites·27 claims
- 1278US11118181B2Compositions and methods for inhibition of expression of protein C (PROC) genesALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Sep 14, 2021·0 cites·20 claims
- 1378US2021388360A1Compositions and methods for inhibition of expression of protein c (proc) genesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1477US12031133B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jul 9, 2024·0 cites·16 claims
- 1577US9963700B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted May 8, 2018·1 cites·24 claims
- 1677US2022251570A1Compositions and methods for inhibiting expression of tmprss6 geneALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1776US2021254063A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGENZYME CORP·Filed 2020·Application pending·0 cites
- 1875US9868949B2Organic compositions to treat EPAS1-related diseasesARROWHEAD RES CORPORATION·Filed 2014·Granted Jan 16, 2018·5 cites·20 claims
- 1973US10538765B2Organic compositions to treat EPAS1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Jan 21, 2020·1 cites·19 claims
- 2073US2020056175A1Compositions and methods for inhibitiion of expression of protein c (proc) genesALNYLAM PHAMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2172US2020216844A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGENZYME CORP·Filed 2018·Application pending·0 cites
- 2271US10954516B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 23, 2021·0 cites·20 claims
- 2370US10273478B2Compositions and methods for inhibition of expression of protein C (PROC) genesALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Apr 30, 2019·0 cites·28 claims
- 2467US11261444B2Organic compositions to treat EPAS1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Mar 1, 2022·0 cites·17 claims
- 2567US9566295B2GNAQ targeted dsRNA compositions and methods for inhibiting expressionALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Feb 14, 2017·0 cites·25 claims
- 2663US2010087508A1Compositions and Methods for Inhibiting Expression of Eg5 and VEGF GenesBUMCROT DAVID·Filed 2009·Application pending·0 cites
- 2761US2014336243A1Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 and VEGF GenesALNYLAM PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2859US2016257954A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2952US8859516B2Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genesBUMCROT DAVID·Filed 2010·Granted Oct 14, 2014·0 cites·20 claims
- 3047US2016000819A1Compositions and Methods for Inhibiting Expression of Eg5 and VEGF GenesALNYLAM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3145US2018153919A1Organic compositions to treat kras-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ivanka Toudjarska files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →